Company Overview and News

2
Meghmani Organics Limited - Investor Presentation

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
M30 MGHOF 532865 MEGH

4
Market Live: Sensex at day#39;s high, Nifty reclaims 10,700; LT up 2% ahead of Q4 nos

2018-05-28 moneycontrol
Buzzing: Capacit’e Infraprojects share price rallied nearly 4 percent after Edelweiss Securities has initiated coverage with Buy rating on the stock and target price of Rs 397.
524715 INDIANB TORNTPHARM MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 GLKQY PRAJIND 532461 500850 INDHOTEL 500650 GLENMARK 522205 514043 INDIGO JETAIRWAYS 533023 532865 539207 TECHM 539448 M30 PNJZY 532296 TQRRY 500420 SUNPHARMA PNB WABCOINDIA EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex at day#39;s high, Nifty inches towards 10,700; LT up 2% ahead of Q4 nos

2018-05-28 moneycontrol
Market Update: The market is trading at day's high, with the Nifty inching towards 10,700 levels following sharp correction in crude oil prices and appreciation in the rupee.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 GLKQY PRAJIND 532461 500650 GLENMARK 522205 514043 INDIGO JETAIRWAYS 533023 532865 539207 TECHM 539448 M30 PNJZY 532296 SUNPHARMA PNB WABCOINDIA EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex strong, Midcap index up over 1%; Nifty IT underperforms

2018-05-28 moneycontrol
Market Update: The market continued to trade strong for the third consecutive day today, with the Sensex rising more than 150 points. Steep fall in crude oil prices and recovery in the rupee from 18-month low boosted investors sentiment.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 PRAJIND 532461 500650 522205 514043 INDIGO JETAIRWAYS 532865 539207 TECHM 539448 M30 PNJZY SUNPHARMA PNB EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex up 200 pts, Midcap extends gains; Manpasand Beverages dips 20%

2018-05-28 moneycontrol
Dr Reddy's Laboratories files lawsuit in US District Court: Shares of Dr Reddy's Laboratories rose 1.3 percent as company filed lawsuit in the United States District Court.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 PRAJIND 532461 500650 522205 514043 INDIGO JETAIRWAYS 532865 539207 TECHM 539448 M30 PNJZY SUNPHARMA PNB EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex reclaims 35K, opens up 100 pts; sharp fall in oil prices lift IOC, HPCL, BPCL

2018-05-28 moneycontrol
Rupee Update: The rupee strengthened by 39 paise to 67.39 against the dollar at the interbank forex market today on fresh selling of the greenback by exporters and banks.
522205 524715 INDIANB INDIGO 514043 MGHOF 532617 HIMATSEIDE 532814 JETAIRWAYS TCHQY 532865 532755 539448 TECHM PRAJIND M30 PNJZY 532461 SUNPHARMA PNB EXCELINDUS MEGH 500650

5
Meghmani Organics gains 3% on stake acquisition in Meghmani Finechem

2018-04-30 moneycontrol
Shares of Meghmani Organics gained 3.6 percent intraday Monday as company acquired 24.97 percent equity stake in Meghmani Finechem.
M30 IFK IFX MGHOF 532865 MEGH

2
Meghmani Organics Limited - Updates

2018-04-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
M30 MGHOF 532865 MEGH

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to NSE:MEGH / MEGHMANI ORGANICS LTD. on message board site Silicon Investor.

MEGALITH CP (MEGH)